Key facts
- This page summarizes Michael L. Levitz's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Mar 2024, 17:23.
Michael L. Levitz - 15 Mar 2024 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)
- Reporting relationship
- EVP, CFO, Treasurer
- Issuer ticker
- ANIK
- Reported as of
- 15 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Mar 2024, 17:23:42 UTC
- Prior SEC filing
- 12 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael L. Levitz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael L. Levitz filed Form 4 for Anika Therapeutics, Inc. (ANIK) on 19 Mar 2024.
Change
- Previous filing in this sequence was filed on 12 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANIK
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +21,329
- Change %
- Price
- $0.000000
- Shares after
- 21,329
- Date
- 15 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,329
- Exercise price
- $0.000000
- Footnotes
- F1
ANIK
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +51,682
- Change %
- Price
- $0.000000
- Shares after
- 51,682
- Date
- 15 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,682
- Exercise price
- $27.98
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
Footnote F2
Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
Footnote F3
The premium priced stock options vest in three equal annual installments beginning on March 15, 2025.